Fig. 5: β-Glucan-polymersome biodistribution and biocompatibility studies in NHPs confirm nanocarriers’ splenic avidity across different species.
From: Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy
a, Schematic representation of the study. 89Zr-labelled β-glucan-polymersomes were intravenously injected in two NHPs that then underwent dynamic and static PET/CT imaging. b, Dynamic PET/CT images at 1 min, 5 min, 15 min, 30 min and 60 min after injections, showing rapid accumulation of 89Zr-β-glucan-polymersomes in the spleen and liver. c, Quantified uptake of 89Zr-β-glucan-polymersomes in representative organs from images in b, indicating higher accumulation in the spleen than other organs, n = 1. d, PET/CT images at 48 h after injections reveal accumulation in the spleen, liver and bone marrow. e, Quantified uptake of 89Zr-β-glucan-polymersomes in representative organs at 48 h from images in d, n = 2. f, Blood chemistry performed on NHP serum taken before (Pre) and 48 h after (Post) 89Zr-β-glucan-polymersome administration, n = 2. The grey boxes indicate reference values1. Alanine transaminase (ALT), aspartate transaminase (AST), creatine and blood urea nitrogen (BUN) levels show no signs of severe toxicity. Schematic illustrations of syringe and NHP were created with BioRender.com.
